Alex Gorsky

Latest Headlines

Latest Headlines

J&J chief hints at unease in China, but plots new buyouts

Johnson & Johnson CEO Alex Gorsky likes to hint at trouble developing its Chinese sales, but don't expect him to come right out and criticize the prickly Chinese government. In an brief interview with The Wall Street Journal, Gorsky said J&J was looking for new acquisitions in China, with new drugs for lung cancer as one of its topic targets.

J&J med tech sales remain relatively flat for second quarter

Second quarter sales for Johnson & Johnson's ($JNJ) medical devices and diagnostics division mirrored those reported in the first quarter, coming in relatively flat at $7.2 billion as sales in its vision and diabetes lines continued to decline due to price competition.

15 Highest-Paid Biopharma CEOs of 2013

Long dominated by global behemoths like Johnson & Johnson and Pfizer, this executive-pay ranking now includes almost as many biotechs as pharma companies.

For J&J, no device growth without Synthes

While Johnson & Johnson touts another strong quarter of device and diagnostics sales, subtracting the effects of its blockbuster deal for Synthes, the company charted almost no med tech improvement over the past year.

J&J consumer operations face problems in Asia but close to resolving them in U.S.

J&J expects its McNeil Consumer Healthcare division to be set free of a two-year-old FDA consent decree by year's end. That order has kept its main OTC plant in Fort Washington, PA, closed and placed strict oversight on two others.

J&J's Gorsky sees McNeil U.S. issues with FDA coming to a close

Johnson & Johnson says that by year's end it can start ticking off the punch list with the FDA at its Fort Washington, PA, manufacturing site, setting the stage for shedding a federal consent decree.

Gorsky pleads with employees to think quality

Another Big Pharma CEO is having a pep talk with employees about manufacturing lapses and the need to reflect on quality.

J&J getting OTC plant problems whipped

In its first-quarter earnings confab, J&J made good on CEO Alex Gorsky's pledge to get the company's troubled OTC manufacturing plants in shape and return the consumer health business to a growing top line.

2012's 10 highest-paid Med Tech CEOs

On FierceMedicalDevices ' list of 2012's 10 highest-paid med tech CEOs, half are serving in their first full year on the job or are new in the position as of this year. Read the full report >>

Ex-J&J chief's 2012 pay outclasses Gorsky's by almost 3-to-1

The question isn't why Johnson & Johnson CEO Alex Gorsky took a 10% hit to his incentive pay. It's why Chairman William Weldon didn't suffer a bigger cut in his pay.